Veranex, a concept-to-commercialisation global service provider dedicated to medtech, has acquired Experien Group, a provider of a full range of regulatory, quality, and clinical consulting services to medtech companies. 

Formed in partnership with global growth investor Summit Partners, Veranex provides the global medical technology industry integrated product development strategies and services across the product life cycle. As a result of this transaction, Veranex’s West Coast operations offer a client-responsive consulting model that adjusts to meet client programme requirements.

David Dockhorn, CEO of Veranex, said: “We are excited to welcome Experien Group to Veranex. With this acquisition, Veranex adds the premier provider of regulatory, quality, and clinical consulting services to medtech companies. Veranex’s clients will benefit from Experien’s long-standing FDA engagement, well-established global regulatory guidance experience, and a demonstrated track record of successful approvals.”

Veranex executive chairman, Pat Donnelly, added: “Experien Group adds another layer of value and medtech insight to Veranex. We will continue to seek additional strategic acquisitions that add depth and resources to the full-service, end-to-end medtech solutions that Veranex has brought to the industry for the first time.”

Financial terms of the transaction were not disclosed.